Why Janux Therapeutics’ JANX011 trial could redefine immune reset in autoimmune disease

Janux Therapeutics begins first human study of JANX011. Find out how CD19 immune reset could change autoimmune treatment strategies.

Janux Therapeutics begins first human study of JANX011. Find out how CD19 immune reset could change autoimmune treatment strategies.